Goodscend#s Vitamin K2 Landed in New York Times Square and Paris Fifteen District, Delivering the Strength of China Intelligence to The World

Food and Healthcare Press Releases Wednesday February 28, 2018 16:44
SHENZHEN, China--28 Feb--PRNewswire/InfoQuest

At the beginning of 2018, Goodscend Pharm. Sci & Tech. Co., Ltd. ("Goodscend") promoted its vitamin brand K2 on the large billboards overlooking New York's Times Square and in the 15th arrondissement of Paris.

Vitamin K2 is recognized by the global healthcare community as a revolutionary vitamin. In 1934, Danish biochemist and physiologist Carl Peter Henrik Dam discovered vitamin K and verified it as a lipid soluble vitamin. Henrik Dam was awarded the Nobel Prize in Medicine in 1943 for joint work with Edward Doisy in discovering vitamin K2. K2 is now widely applied in research for the prevention of osteoporosis, arteriosclerosis and cancer in developed markets, including Europe, the United States and Japan.

Goodscend is a large high-tech healthcare company engaged in the research and development as well as the production and marketing of healthcare and pharmaceutical products. The company has attracted much attention as a result of the ongoing expansion of its presence in international markets. Leading global market intelligence provider HTF Market Intelligence Consulting Private Limited said in its 2017 report that Goodscend's MK-4, an active pharmaceutical ingredient (API) of its K2 products, continues to claim a leading position in terms of the market share worldwide and is now available in 17 countries and regions, supported by long-term partnerships with several leading global healthcare product companies.

High-purity vitamin K2

Goodscend continues to build on its technological advantages by developing proprietary high value-added and high-tech products. With years of continuous improvement in production technologies for K2 products, the purity of Goodscend's MK-4, MK-7 and MK-9 has reached 98 percent. The series of vitamins are among those with the highest percentage of active ingredients worldwide.

Forging ahead with the aim of becoming an industry leader

As a low-profile global leader in terms of the sales of K2's API MK-4, Goodscend continues in its commitment to the development of vitamin K2 healthcare products. Goodscend's K2, a fast-growing brand in the healthcare product industry, has also taken the message of the power of intelligent manufacturing in China to the world with the appearance on the large billboards overlooking New York's Times Square and in the 15th arrondissement of Paris.

Contact:
Tel:+86-755-26808826
Email: vksale@goodscend.com
Website: http://www.goodscend.com
Photo - https://photos.prnasia.com/prnh/20180228/2067856-1

Latest Press Release

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

BookDoc collaborates with Chow Tai Fook: Get more rewards by staying active together with Chow Tai Fook

Chow Tai Fook is collaborating with BookDoc, the largest integrated healthcare app in Southeast Asia by healthcare network in giving more rewards to BookDoc users for maintaining an active healthy lifestyle. Users can now enjoy discounts and redeem...

MEDICAL WINGS THAILAND BASED AIR AMBULANCE OPERATOR ACHIEVES FULL ACCREDITATION FROM CAMTS AND CAMTS EU AND BECOMES THE FIRST OPERATOR IN ASIA TO ACHIEVE THE #DUAL ACCREDITATION

Medical Wings, the air ambulance division of Siam Land Flying Company, a subsidiary company of Charoen Pokphand Group (C.P. Group), is proud to achieve full re-accreditation of its existing CAMTS approval as well as attaining the new CAMTS EU...

Photo Release: CGH Group Hospital held the event Happy Life with Healthy Bone and Joints Seminar in Yangon, Myanmar.

CGH Group Hospital recently held a live health talk in Yangon, Myanmar to highlight the important health issues on bone and joints for all Myanmar people. A team of medical experts led by Dr. Wanchai Sirisereewan (4th from left), CGH's Orthopedic Surgeon...

BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

- First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a regulatory submission in the US and...

Related Topics